Generated by AI
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.
Website215 Church Street
New Haven, CT, 06510
United States
The latest articles about BHVN.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Summary of Sep 10's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about BHVN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.